Menten AI is a drug discovery company focused on designing peptides for conditions with high unmet medical need. We develop computational methods for protein design that leverage machine learning and quantum computing.

Menten AI was founded by Hans Melo.

The CEO of Menten AI is Hans Melo. You can find more information about them on their LinkedIn profile.

Menten AI has raised a total of $$6 million across 3 funding rounds. The most recent funding was completed on 2023-06-05.

Menten AI's key investors include Uncork Capital, Social Impact Capital, Khosla Ventures, Y Combinator.

Menten AI is headquartered in San Francisco, United States.

Menten AI was founded in 2018.

Menten AI has 11-50 employees.

You can visit Menten AI's official website at http://menten.ai.

Menten AI's latest funding round was a Seed round of $$6 million completed on 2023-06-05.

Hans Melo

Menten AI is a drug discovery company focused on designing peptides for conditions with high unmet medical need using computational methods that leverage machine learning and quantum computing.

$6 million

2023-06-05

Uncork Capital Social Impact Capital Khosla Ventures Y Combinator

Scaling business operations Integrating quantum computing with AI

Expanding market for peptide therapeutics Collaborations with other biotech firms

Menten AI partners with Xanadu to develop quantum machine learning solutions for drug discovery. Menten AI collaborates with Xanadu to innovate drug design using quantum computing and classical methods.